Calquence
Payments companies reported to CMS as associated with Calquence. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Calquence, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Calquence
These are the largest totals companies reported as associated with Calquence. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Alan Zausner Skarbnik | Charlotte, NC | Hematology (Internal Medicine) | $189,098.10 |
| Javier Pinilla-Ibarz | Tampa, FL | Hematology (Internal Medicine) | $157,941.30 |
| Catherine Coombs | Orange, CA | Hematology & Oncology | $149,672.00 |
| Johnny Chang | Encino, CA | Hematology & Oncology | $131,726.55 |
| Kashif Ali | Silver Spring, MD | Hematology & Oncology | $97,018.48 |
| Moshe Levy | Dallas, TX | Medical Oncology | $95,760.67 |
| Stephanie Bernstein | Winchester, MA | Hematology & Oncology | $95,425.00 |
| Sanjay Sharma | Fullerton, CA | Medical Oncology | $94,235.21 |
| Michael Bishop | Chicago, IL | Hematology & Oncology | $87,504.54 |
| Noam Drazin | Beverly Hills, CA | Medical Oncology | $81,801.32 |
Prescribed Calquence?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.